FineHeart is a French medical device company focused on creating innovative technologies in the cardiovascular space. The patented FineHeart invention, the ICOMS FLOWMAKER® (Implantable Cardiac Output Management System) is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the heart's natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients' needs, like a pacemaker to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, and lasts on average 90 minutes. Heart Failure (HF) is the second leading cause of death in the US and in Europe. It is a disease with high mortality rates, and repeated and extended hospitalizations. One out of every five patients die within the year following diagnosis. The average annual cost for the hospital to follow patients is up to €77K with 70% of the cost linked to hospitalization. FineHeart was founded by a team of internationally renowned cardiologists and managers from the Medtech Industry, led by Arnaud Mascarell (CEO), Dr. Stéphane Garrigue (CSO) and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy. Their vision became the FineHeart's mission: developing and offering to patients a miniaturized, fully implantable, pulsatile circulatory support system that would overcome many of the challenges associated with left ventricular assist devices (LVADs) currently on market. The overarching goal is to restore normal cardiac output and allow heart failure patients to return to a normal quality of life.